Exane BNP Paribas Downgrades Novo Nordisk (NVO) to Underperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
BofA/Merrill Lynch Downgrades Novo Nordisk (NVO) to Neutral
June 17, 2013 7:17 AM EDTBofA/Merrill Lynch downgraded Novo Nordisk (NYSE: NVO) from Buy to Neutral.
For an analyst ratings summary and ratings history on Novo Nordisk click here. For more ratings news on Novo Nordisk click here.
Shares of Novo Nordisk closed at $167.58 yesterday, with a 52 week range of $135.61-$194.44.... More
